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Allergic rhinitis and asthma often coexist and share a genetic back-
ground. Pathophysiologic connections between the nose and
lungs are still not entirely understood. This study was undertaken
to compare allergic inflammation and clinical findings in the upper
and lower airways after segmental bronchial provocation (SBP) in
nonasthmatic allergic rhinitis patients. Eight nonasthmatic, grass
pollen-sensitive patients with allergic rhinitis and eight healthy
controls were included. Bronchial biopsies and blood samples were
 
taken before (T
 
0
 
) and 24 h (T
 
24
 
) after SBP. Nasal biopsies were
obtained at T
 
0
 
, 1 h after SBP (T
 
1
 
), and T
 
24
 
. Immunohistochemical
staining was performed for eosinophils (BMK13), interleukin (IL)-5,
and eotaxin. The number of eosinophils increased in the chal-
lenged and unchallenged bronchial mucosa (p 
 
,
 
 0.05) and in the
blood (p 
 
5
 
 0.03) of atopic subjects at T
 
24
 
. We detected an increase
of BMK13-positive and eotaxin-positive cells in the nasal lamina
propria and enhanced expression of IL-5 in the nasal epithelium
of atopic subjects only at T
 
24
 
 (p 
 
,
 
 0.05). SBP induced nasal and
bronchial symptoms as well as reductions in pulmonary and nasal
function in the allergic group. No significant changes could be ob-
served in healthy controls. The study shows that SBP in nonasth-
matic allergic rhinitis patients results in peripheral blood eosino-
philia, and that SBP can induce allergic inflammation in the nose. 
 
Epidemiologic (1), pathophysiologic (2, 3), and clinical studies
(4, 5) strongly suggest a link between rhinitis and asthma.
Asthma and rhinitis, which are considered to be manifesta-
tions of the atopic syndrome, often coexist and share a com-
mon genetic background. Although several studies have shown
that asthma and rhinitis are characterized by a similar inflam-
matory process (6–9), pathophysiologic interactions between
upper and lower airways are not entirely understood. It is
clear that the condition of the upper airways definitely influ-
ences the lower airways. In allergic rhinitis patients without
bronchial hyperreactivity (BHR), signs of allergic inflamma-
tion of the lower airways have been found in induced sputum,
bronchoalveolar lavage fluid (BALF), and bronchial biopsy
specimens (10–13). The nasal-bronchial reflex, an altered breath-
ing pattern, pulmonary aspiration of nasal contents, and in-
creased levels of inflammatory factors in the blood are possi-
ble mechanisms for lower airway dysfunction among patients
with rhinitis (14). To shed more light on the role of systemic
induction in the allergic inflammatory response, we designed a
study in which blood samples and nasal and bronchial mucosal
biopsy specimens were taken from a group of nonasthmatic al-
lergic rhinitis patients with an isolated grass pollen allergy af-
ter segmental bronchial provocation (SBP) at a time other than
the grass pollen season. The aim of the study was to compare
allergic mucosal inflammation and clinical findings in the upper
and lower airways. Eosinophils, major effector cells in allergic
inflammation, interleukin (IL)-5–positive cells and eotaxin-pos-
itive cells (necessary for eosinophil survival and chemotaxis),
were chosen as markers of mucosal allergic inflammation.
 
METHODS
 
Subject Groups
 
Eight allergic rhinitis patients (two men and six women, age range 21
to 31 yr) and eight nonallergic healthy controls (four men and four
women, age range 18 to 29 yr) were selected for the study. Subject
characteristics are shown in Table 1. The rhinitis patients had a his-
tory of isolated grass pollen allergy for at least 2 yr, confirmed by a
positive skin-prick test reaction to grass pollen extract alone (Vivodiag-
nost; ALK Benelux BV, Groningen, the Netherlands), and not to a
panel of 13 other common allergens. The control subjects had no
symptoms or signs of rhinitis and had negative skin-prick tests. None
of the allergic rhinitis patients or controls had a clinical history of
 
asthma. All had a normal FEV
 
1
 
 and provocative concentration of
methacholine causing a 20% decrease in FEV
 
1
 
 (PC
 
20
 
 methacholine)
 
.
 
 8 mg/ml. Methacholine was administered according to a standard-
ized tidal breathing method (15). The response to methacholine was
measured as change in FEV
 
1
 
, expressed as a percent of the initial
value. None of the subjects smoked or used any medication known to
influence the results of the study. Biopsy specimens were obtained be-
tween February and April 1998, before the grass pollen season. None
of the patients or control subjects had an infection of the respiratory
tract or any nasal complaints during the 4 wk preceding the allergen
challenges. All participants gave informed consent to the study, which
was approved by the medical ethics committee of the Erasmus Medi-
cal Center Rotterdam.
 
Experimental Design
 
The study design is outlined in Table 2. Baseline nasal and bronchial
biopsy specimens were collected from patients and controls before
SBP (T
 
0
 
). Nasal biopsy specimens were obtained 1 h (T
 
1
 
) and 24 h
(T
 
24
 
) after SBP. Bronchoscopy and biopsy were repeated 24 h after
SBP (T
 
24
 
). Signs and symptoms of the patients and controls were re-
corded at the beginning of each visit (at T
 
0
 
 and T
 
24
 
) on a 10-cm visual
analogue scale (VAS). Symptoms were divided into nasal complaints
(rhinorrhea, watery eyes, nasal itching, sneezing, and nasal blockage)
and pulmonary complaints (wheezing, coughing, shortness of breath,
and decreased exercise tolerance). Upper and lower airways obstruc-
tion was measured through peak nasal inspiratory flow (PNIF) and
FEV
 
1
 
. FEV
 
1
 
 was determined at T
 
0
 
, T
 
1
 
, and T
 
24
 
. PNIF was measured
with a Youlten peak nasal inspiratory flow meter (Armstrong Indus-
tries, Inc., Northbrook, IL) at T
 
0
 
 and T
 
24
 
. Blood samples were taken at
T
 
0
 
 and T
 
24
 
. Blood eosinophils were counted by hemocytometry.
 
Bronchial Biopsies and Segmental Allergen 
Bronchoprovocation
 
All bronchial biopsy specimens were taken by the same pulmonary
physician (S.E.O.). After intramuscular premedication of subjects
with atropine (0.5 mg), oropharyngeal anesthesia was accomplished
with topical 1% xylocaine spray. The vocal cords, trachea, and bron-
chial tree were then anesthesized with oxybuprocaine. A fiberoptic
bronchoscope was introduced into the airway via the oral route, and
mucosal biopsy specimens were taken from the carina of the left up-
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per and lower lobe. Subsequently, SBP was accomplished with a
method described previously (16). The tip of the bronchoscope (BF,
Type P20 D; Olympus Tokyo, Japan), was wedged in the anterior seg-
ment of the right upper lobe (RUL), and 10 ml of 0.9% sterile saline
was instilled as a control challenge. After the control challenge, the
bronchoscope was wedged in a segmental bronchus of the right mid-
dle lobe (RML), and allergen challenge was achieved by instilling 100
BU of grass pollen extract (Vivodiagnost) made up in 5 ml of sterile
saline. The challenge site was observed for 5 min. In the absence of lo-
cal bronchoconstriction, a further 400 BU of allergen in 5 ml of saline
was administered, after which the bronchial segment was observed for
5 more minutes and the bronchoscope then quickly removed. After
24 h, each subject underwent a repeat bronchoscopy, during which bi-
opsy specimens were taken from lobar segments of the unchallenged
left side, the saline-challenged RUL and the allergen-challenged
RML. The biopsy specimens were embedded in Tissue-Tek II optimal
cutting temperature (OCT) compound (Sakura Finetek USA Inc.,
Torrance, CA), frozen, and stored at 
 
2
 
150
 
8
 
 C.
 
Nasal Biopsies
 
All biopsy specimens of nasal mucosa were taken by the same investi-
gator (G.J.B.) according to the study design shown in Table 2. First,
local anesthesia was induced by placing a cotton-wool carrier with 50
to 100 mg of cocaine and 3 drops of epinephrine (1:1,000) under the
inferior turbinate, without touching the biopsy site. Second, mucosal
biopsy samples were obtained from the lower edge of the inferior tur-
binate, about 2 cm posterior to the edge, by using a Gerritsma for-
ceps with a cup diameter of 2.5 mm. The nasal biopsy specimens were
 
embedded in Tissue-Tek II OCT compound, frozen, and stored at
 
2
 
150
 
8
 
 C. (17).
 
Monoclonal Antibodies
 
The monoclonal antibodies (mAbs) used in the study were BMK-13
(IgG
 
1
 
, 0.2 
 
m
 
g/ml; Sanbio, Uden, The Netherlands) for total eosino-
phils, an antibody to human (IL)-5 (IgG
 
1
 
, 50 
 
m
 
g/ml; clone 5A5, a gift
from Prof. Jan Tavernier of the University of Ghent, Ghent, Bel-
gium), and an anti-eotaxin antibody (IgG
 
1
 
, 10 
 
m
 
g/ml; clone 43911.11;
R&D Systems, Minneapolis, MN).
 
Immunohistochemical Staining
 
Staining for eosinophils with BMK13 was done with a modified al-
kaline phosphatase (AP) method (18). (IL)-5 and eotaxin staining
were done as follows: briefly, each tissue specimen was cut into serial,
6-
 
m
 
m–thick sections on a Reichert–Jung 2800e Frigocut cryostat (Leica,
Wetzlar, Germany) and transferred onto poly-
 
L
 
-lysine–coated slides
(Sigma Chemical Co., St. Louis, MO), dried, and stored at 
 
2
 
70
 
8
 
 C. The
slides were stained within 3 mo. They were heated to room temperature
and subsequently dried and fixed in acetone for 10 min at room tem-
perature. The slides were then rinsed in phosphate-buffered saline
(PBS; pH 7.8) and placed in a semiautomatic stainer (Sequenza; Shan-
don, Sewickley, PA). Sections were incubated with 10% normal goat
serum (CLB, Amsterdam, The Netherlands) for 10 min and were sub-
sequently incubated for 60 min with the appropriate mAb (diluted in
10% normal human serum with 1% bovine serum albumin in PBS).
They were then rinsed with PBS for 5 min, incubated with biotin-
labeled goat-antimouse (Biogenex, San Ramon, CA), rinsed with
PBS, incubated with AP-conjugated goat-antibiotin (Sigma) for 30
min, rinsed once more with PBS for 5 min, rinsed with Tris buffer (0.2
mol/L, pH 8.5) for 5 min, and incubated for 30 min with new fuch-
sin (Chroma, Köngen, Germany) substrate (containing levamisole to
block endogenous AP enzyme activity). The sections were then rinsed
in distilled water, counterstained with Gill’s hematoxylin, and mounted
in glycerin gelatin. Control staining was done with an irrelevant mAb
of the same subclass as the specific antibody.
 
Microscopic Evaluation
 
Biopsy specimens were coded, and two sections 120 
 
m
 
m apart were
counted in a blinded fashion for each antibody. Bronchial sections
were divided into epithelium and subepithelium (an area 100 
 
m
 
m
deep in the lamina propria, along the length of the epithelial base-
ment membrane) and were counted as previously decribed (19). Nasal
biopsy sections were divided into epithelium, subepithelium, and lam-
ina propria (total subepithelial mucosa). Positively stained epithelial
and subepithelial cells were counted along the basement membrane,
which had to be undamaged for a length of at least 1 mm before being
accepted for evaluation. For lamina propria, a minimum area of 1 mm
 
2
 
was required for analysis. Cell numbers were determined as the num-
ber of positively stained cells per mm
 
2
 
, using an Axioskop 20 micro-
scope (Zeiss, Jena, Germany) with an eyepiece graticule at a magnifi-
cation of 
 
3
 
200. 
 
Statistical Analysis
 
Statistical analysis was done with Friedman’s and Wilcoxon’s test for
intragroup analysis and the Mann–Whitney U test for intergroup
analysis. Data are presented as median 
 
6
 
 range. Correlations were
evaluated with Spearman’s rank correlation test. A value of p 
 
,
 
 0.05
was considered significant.
 
RESULTS
 
Clinical Data
 
The allergic rhinitis patients reported significantly more pulmo-
nary symptoms after SBP than did the controls (Table 3), ex-
pressed by an increased total bronchial VAS score at T
 
24
 
 (p 
 
5
 
0.03). A significant decrease in FEV
 
1
 
, of 9% (range: 
 
2
 
20 to
 
1
 
3%), was measured at T
 
1
 
 in allergic patients (p 
 
5
 
 0.03),
whereas in controls, FEV
 
1
 
 barely changed (median: 
 
2
 
1%;
range: 
 
2
 
4 to 
 
1
 
4%). At T
 
24
 
, FEV
 
1
 
 was still 9% (range: 
 
2
 
11 to
0%) lower than its baseline value in allergic patients, and only
 
TABLE 1
SUBJECT CHARACTERISTICS AT BASELINE*
 
Patient
Age
(
 
yr
 
) Sex
FEV
 
1
 
(
 
L
 
)
FEV
 
1
 
(
 
%
 
)
IVC
(
 
L
 
) FEV
 
1
 
/VC
BAR*
(
 
%
 
)
PC
 
20
 
(
 
mg/ml
 
)
Allergic rhinitis
1 31 F 4.00 108 4.99 80 102 40
2 21 M 4.02 85 5.15 79 107 11.8
3 25 F 4.74 126 5.62 84 102 23.6
4 25 M 4.35 94 5.44 80 104 40
5 27 F 3.71 114 4.06 91 100 40
6 23 F 3.91 113 4.54 86 104 40
7 23 F 4.00 122 4.65 86 105 40
8 21 F 4.06 111 4.70 86 100 40
Controls
9 23 F 2.96 82 3.43 86 110 40
10 29 M 5.59 115 7.42 76 108 32.4
11 24 M 4.14 94 4.72 88 101 40
12 28 F 2.52 80 2.67 95 102 40
13 25 F 4.21 112 4.72 89 101 40
14 21 M 5.99 100 6.98 86 102 40
15 20 M 4.81 114 5.44 88 102 9
16 18 F 3.83 111 5.12 76 107 40
 
Definition of abbreviations
 
: BAR 
 
5
 
 
 
b
 
-agonist response; IVC 
 
5
 
 inspiratory vital capacity;
PC
 
20
 
 
 
5
 
 concentration of methacholine causing a 20% decrease in FEV
 
1
 
.
* BAR (terbutaline, 1,000 
 
m
 
g) data are presented as percentage improvement com-
pared to initial value; a virtual value of 40 was assigned to subjects who did not reach a
PC
 
20
 
 with 38 mg/ml methacholine.
 
TABLE 2
STUDY DESIGN
 
Time Point
VAS
Score FEV
 
1
 
PNIF
Bronchial
Biopsy
Nasal
Biopsy
Blood
Samples
T
 
0
 
Baseline X X X X X X
T
 
1
 
1 h after SBP* X X
T
 
24
 
24 h after SBP X X X X X X
 
Definition of abbreviations
 
: PNIF 
 
5
 
 peak nasal inspiratory flow; SBP 
 
5
 
 segmental
bronchial provocation; VAS 
 
5
 
 visual analogue scale for scoring nasal and pulmonary
symptoms.
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2% (range: 
 
2
 
9 to 0%) below its baseline value in healthy con-
trols. Also, the nasal VAS score was significantly increased (p 
 
5
 
0.02) and PNIF was reduced (p 
 
5
 
 0.02) at T
 
24
 
, as compared with
their baseline values in the allergic group. No effect on either na-
sal VAS score or on PNIF could be detected in control subjects.
 
Blood Eosinophils
 
No significant difference in baseline blood eosinophil count
was observed in allergic patients (median: 175 
 
3
 
10
 
6
 
/L; range:
70 to 440 
 
3
 
10
 
6
 
/L) as compared with healthy controls (median:
95 
 
3
 
10
 
6
 
/L; range: 40 to 190 
 
3
 
10
 
6
 
/L). Twenty-four hours after
SBP, total blood eosinophil counts were significantly elevated
over baseline in allergic patients (p 
 
5
 
 0.02) and as compared
with those of controls (p 
 
5
 
 0.001; Figure 1).
 
Immunostaining
 
General description
 
. Three nasal mucosa specimens and four
bronchial biopsy specimens were collected per patient. Of the
112 biopsy specimens, 106 met the criteria for evaluation. Nei-
ther bronchial epithelium (median length of evaluable base-
ment membrane: 3.6 mm; range: 0 to 7.8 mm) nor subepithe-
lium (median: 3.4 mm; range: 0 to 7.8 mm) could be evaluated
in five samples. Nasal epithelium (median: 5.2 mm; range: 1.1
to 12.5 mm), subepithelium (median: 5.4 mm; range: 1.1 to
12.5 mm), and lamina propria (median: 4.63 mm
 
2
 
; range: 0.88
to 8.31 mm
 
2
 
) could not be evaluated in one case. These sam-
ples were excluded from the study. However, for all time points,
a minimal number of seven subjects per subgroup could be in-
cluded.
 
Bronchial specimens
 
. In bronchial epithelium, baseline
(BMK13-positive) BMK13
 
1
 
 cell numbers were equal in aller-
gic subjects and controls (Figure 2A). In the subepithelium,
BMK13
 
1
 
 cell numbers were higher in atopic than in control
subjects (p 
 
,
 
 0.01), but absolute cell numbers were very low at
baseline (Figure 2B). At T
 
24
 
, we found increased numbers of
BMK13
 
1
 
 cells in the bronchial epithelium and subepithelium
of allergic rhinitis patients (Figure 3), in the saline-challenged
bronchial segment (epithelium, p 
 
5
 
 0.02; subepithelium p 
 
5
 
0.03) as well as in the allergen-challenged bronchial segment
(epithelium, p 
 
5
 
 0.01; subepithelium, p 
 
5
 
 0.02). In the unchal-
 
TABLE 3
CLINICAL DATA FOR ALLERGIC RHINITIS PATIENTS AND
CONTROLS BEFORE (T
 
0
 
) AND 24 h (T
 
24
 
) AFTER SBP
SEGMENTAL BRONCHIAL PROVOCATION
 
FEV
 
1
 
(
 
L
 
)
PNIF
(
 
L
 
) Lung Symptoms Nose Symptoms
Patient T
 
0
 
T
 
24
 
T
 
0
 
T24 T0 T24 T0 T24
Allergic rhinitis
1 4.00 3.82 235 190 6 37 7 56
2 4.02 4.05 265 250 26 68 52 128
3 4.74 4.34 200 180 0 123 0 35
4 4.35 4.21 270 260 36 16 35 35
5 3.71 3.35 230 220 24 31 46 54
6 3.91 3.94 220 215 13 34 0 47
7 4.00 3.77 250 230 10 27 36 49
8 4.06 3.64 220 220 8 50 12 28
Controls
9 2.96 2.97 120 115 na na na na
10 5.59 5.13 290 185 28 15 36 53
11 4.14 4.10 160 240 4 9 7 6
12 2.52 2.46 230 240 31 68 49 203
13 4.21 4.08 235 205 7 6 19 63
14 5.99 4.69 300 265 8 30 11 43
15 4.81 5.68 180 195 21 24 56 53
16 3.83 3.62 230 210 3 10 10 17
Definition of abbreviations: na 5 not available; PNIF 5 peak nasal inspiratory flow;
VAS 5 visual analogue scale.
Symptoms were individually expressed in mm on a 10-cm visual analogue scale, and
a composite score was obtained for nasal complaints (rhinorrhea, watery eyes, nasal
itching, sneezing, and nasal discharge) and pulmonary complaints (wheezing, cough-
ing, shortness of breath, and decreased exercise intolerance).
* p , 0.05.
Figure 1. Number of peripheral blood eosinophils before (T0) and 24 h
(T24) after SBP. Grey boxes indicate allergic patients, open boxes indicate
controls. Data are presented as median 6 range. *p , 0.05, **p , 0.01.
Figure 2. Number of BMK131 cells in bronchial epithelium (A) and
subepithelial layer (B) before (T0) and 24 hours (T24) after SBP. A 5 un-
challenged left lung; B 5 allergen challenged right middle lobe; C 5
saline challenged right upper lobe. Grey boxes indicate allergic pa-
tients, open boxes indicate controls. Data are presented as median 6
range. *p , 0.05, **p , 0.01.
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Figure 3. BMK13 immunoreactivity of a section of bronchial biopsy taken from an allergen-challenged segment of an allergic rhinitis patient 24 h
after SBP. Counterstained with hematoxylin. Original magnification: 3400.
Figure 4. Number of BMK131 cells in nasal epithelium (A) and lamina
propria (B) before (T0) and 1 h (T1) and 24 h (T24) after SBP. Grey boxes
indicate allergic patients, open boxes indicate controls. Data are pre-
sented as median 6 range. *p , 0.05.
lenged segment, BMK131 cell numbers were not significantly
affected by SBP (p 5 0.07 for both epithelium and subepithe-
lium). At T24 we found a significant difference between aller-
gic patients and controls in the number of eosinophils in the
allergen-challenged segment (epithelium, p 5 0.003; subepi-
thelium, p 5 0.002), saline challenged segment (epithelium, p 5
0.01; subepithelium, p 5 0.03), and even in the unchallenged
segment (epithelium, p 5 0.001; subepithelium, p 5 0.001). In
none of the tissue areas of the control groups, were BMK131
cell numbers significantly altered at T24.
After SBP, IL-5–positive cell numbers were markedly in-
creased only in the allergen-challenged bronchial subepithe-
lium in allergic rhinitis subjects (p 5 0.07). No significant dif-
ferences were found in the other investigated segments.
No significant changes were found in the number of eo-
taxin-positive cells in bronchial mucosa from before to after
SBP.
Nasal specimens. Although at T0, BMK13
1 cell numbers in
the nasal epithelium (Figure 4A) and subepithelium were
slightly higher in the allergic group than in the controls, no dif-
ferences were found at T1 and T24 as compared with baseline
or between the two groups. BMK131 cell numbers were not
significantly different in the lamina propria of the allergic and
control groups at T0 (Figure 4B). At T24, however, the number
of BMK131 cells in the nasal lamina propria was significantly
greater in allergic patients than at baseline (p 5 0.04). A sig-
nificant increase in the number of IL-5–positive cells was found
in the nasal epithelium at T24 (p 5 0.02; Figures 5A and 6). The
numbers of IL-5–positive cells in the nasal subepithelium and
lamina propria were increased (Figure 5B), but this did not
reach significance.
In the nasal epithelium, the eotaxin-positive cell number
was significantly increased at T24 as compared with that at T1
(p 5 0.05) in allergic patients, but not in controls. As com-
pared with baseline, eotaxin-positive cells were significantly
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increased in the subepithelium (p 5 0.01) and lamina propria
(p 5 0.03) of the nasal mucosa at T24 in allergic patients, but
not in controls. However, differences between allergic patients
and controls did not reach statistical significance.
Comparison of nasal and bronchial inflammatory cell num-
bers. At baseline, the numbers of eosinophils, IL-5–positive
cells, and eotaxin-positive cells in rhinitis patients and controls
were low and not statistically different in bronchial and nasal
biopsy specimens. The reason that only epithelial and subepi-
thelial layers were compared is because of the difference in
size between nasal and bronchial biopsy specimens. In atopic
patients, the eosinophil number at T24 was higher in bronchial
mucosa (RML) than in nasal mucosa for both epithelium (p 5
0.02) and subepithelium (p 5 0.01). In controls, no differences
were found. In allergic patients, the number of IL-5–positive
cells at T24, however, was significantly greater in the nasal sub-
epithelial layer than in the bronchial subepithelium (p 5 0.01),
but this was not found in controls. In both atopic subjects and
controls, the number of eotaxin-positive cells at T24 was
greater in the epithelium and subepithelium of the nasal mu-
cosa than in the bronchial mucosa, but the difference did not
reach statistical significance.
Correlations between inflammatory markers, airway func-
tion and symptomatology. In the allergic subgroup, the num-
ber of bronchial eosinophils (RML) correlated with the num-
ber of blood eosinophils (epithelium Spearman’s r 5 0.56, p 5
0.03; subepithelium: r 5 0.49, p 5 0.05). No correlation could
be found between nasal inflammatory cell numbers, PNIF,
and nasal symptom score.
A correlation was found between the increase in bronchial
eosinophils (subepithelium, RML) and the total nose symp-
tom score in atopic subjects (r 5 0.57, p 5 0.02), which was not
found in the controls. In the allergic subgroup, total nose
symptom score and total lung symptom score were highly cor-
related (r 5 0.57, p 5 0.02). No correlation was found between
symptom scores and airway function (FEV1 and PNIF).
Figure 6. IL-5 immunohistochemical staining of a section of a nasal biopsy taken from an allergic rhinitis patient 24 h after SBP. Counterstained
with hematoxylin. Original magnification: 3200.
Figure 5. Number of IL-5–positive cells in nasal epithelium (A) and
lamina propria (B) before (T0) and 1 h (T1) and 24 h (T24) after SBP.
Grey boxes indicate allergic patients, open boxes indicate controls. Data
are presented as median 6 range. *p , 0.05.
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DISCUSSION
In this study, we were able to demonstrate allergic inflamma-
tion, characterized by eosinophil infiltration, in the bronchi of
subjects with nonasthmatic allergic rhinitis at 24 h after SBP.
This occurred not only in allergen-challenged, but to a lesser
extent also in saline-challenged and control segments. These
data suggest a more generalized effect on the lower airways af-
ter local allergen deposition, which is also reflected by a sus-
tained decrease in FEV1 and increase in pulmonary symptoms
after SBP in allergic subjects. The increased nasal obstruction
and symptom score at 24 h after SBP in allergic rhinitis patients
indicate that the upper respiratory tract is also involved in the
allergic response. Peripheral blood eosinophilia and increased
eosinophil numbers deep in the nasal mucosa after SBP further
support the idea that a more extended systemic inflammatory
reaction takes place in these nonasthmatic patients. Although
other authors have also reported activation and mobilization of
blood eosinophils in nonasthmatic allergic subjects after SBP
(12, 20), we have found no published reports of signs of allergic
inflammation in a remote and “upstream” organ after local al-
lergen challenge. Generalized pulmonary inflammation cannot
be explained by bronchoscopic and biopsy findings, per se (21).
To minimize intraluminal spread of antigen from the allergen-
challenged bronchial segment to other segments, we held the
bronchoscope in the wedged position for 5 min, as has been
suggested by other authors (11). It is also very unlikely that al-
lergen spilled into the nose after SBP, since we performed
bronchoscopy by the oral route, and it did not lead to excessive
coughing. Other mechanisms that are more likely to explain
the interaction between the nose and the lung are neural reflex
mechanisms and systemic induction of inflammatory mediators
and cells. Our results are most suggestive of a general systemic
activation of eosinophils, which leads to migration of these
cells into both the upper and lower respiratory mucosa. The
detection of increased expression of the proeosinophilic cyto-
kines (IL)-5 and granulocyte–macrophage colony-stimulating
factor in the serum of allergic rhinitis patients after nasal aller-
gen provocation supports our hypothesis (22). Nasal provoca-
tion with methacholine in asthmatic patients with rhinitis re-
sulted in an increase in lower airway resistance that could be
blocked by premedication of the nasal mucosa with phenyleph-
rine, also suggesting a role for systemic absorption in the induc-
tion of lower airway resistance (23). The contribution of a
bronchonasal reflex mechanism to nasal allergic inflammation
after SBP is currently under investigation.
Several studies have demonstrated the role of IL-5 and eo-
taxin in the influx of eosinophils into the mucosa (24–26). Previ-
ous studies involving allergic rhinitis and asthma patients have
shown a significant increase in IL-5 concentrations in BALF af-
ter SBP (11, 27, 28). We could also demonstrate an increased
expression of both IL-5 and eotaxin in the bronchial mucosa of
allergic patients 24 h after SBP. The increase did not reach sta-
tistical significance, but this could have been due to the rela-
tively late time point of sampling and the brief, transient pres-
ence of these cytokines in the bronchial tissue. A significant
increase in both IL-5–positive and eotaxin-positive cells, coin-
ciding with the influx of eosinophils into the nasal lamina pro-
pria, was detected in the nasal mucosa at 24 h after SBP, illus-
trating a delay in activation of the inflammatory pathway in the
nasal mucosa as compared with the bronchial mucosa.
Several investigators have shown that eosinophilic inflam-
mation of the airways is correlated with the severity of asthma
(6, 29). In our study, we also found a strong correlation of clin-
ical data (FEV1 and VAS score) with inflammatory parame-
ters (eosinophils and IL-5 expression) in allergic lower air-
ways, but were unable to demonstrate any correlation between
clinical parameters and inflammatory cell numbers in the
nose. Some authors (30, 31) reported a correlation between
the number of eosinophils or mediators released by eosino-
phils and symptoms after nasal provocation. Usually, no corre-
lation was found (18, 32, 33).
It is not clear why allergic rhinitis patients without BHR do
not have asthma in the natural situation. Our results have led
us to hypothesize that allergic rhinitis patients do have asthma,
but that the dose of allergen required to initiate an allergic re-
sponse in the bronchi is probably higher in allergic rhinitic
than in clinical asthma patients. Although the type and degree
of inhalant allergy are known to play important roles in the
mechanism underlying nonspecific BHR (34), other factors,
such as duration and severity of exposure, could also affect the
clinical manifestation of the allergic response.
In conclusion, we have found an allergic inflammatory re-
sponse, similar to asthma, in the lower airways of rhinitis pa-
tients without BHR after SBP. Interestingly, the allergic re-
sponse was not restricted to the allergen-challenged bronchial
segment, but was more widespread: eosinophilia also occurred
in other parts of the lung, and was detectable in peripheral
blood. Moreover, we found increased inflammatory cell num-
bers in the nasal mucosa after SBP, together with signs and
symptoms of allergic rhinitis, indicating that the nose is also
involved in this systemic effect. We also observed a clear dif-
ference in the time course and the degree of clinical and im-
munopathologic findings in the nose and bronchi of allergic
subjects after local allergen challenge.
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